Dossier assessment
Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Patients with solid tumours that display an NTRK gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options
Added benefit not proven due to lack of suitable study data
Press releases
Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient for derivation of an added benefit
Additional information
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.
Project details
- Project no.
- A19-90
- Commission
- Commission awarded on 15.10.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90
Status: Commission completed